Skip to main content

Humanized Models of Disease (HMD) Core

Overview

The Humanized Models of Disease (HMD) Core provides investigators humanized mouse models to effectively conduct translatable research in biomedicine. Humanized mouse models are particularly suited to the investigation of disease and development of therapeutics. The objective of Core service is to deliver standard BLT humanized mice, Wistar humanized mice (WH mice: BLT+ AAV cocktail), archiving/provision of tumor tissues-generation of patient-derived xenograft mice (PDX mice), and the development of primary organoid (tumor) tissue cultures. Cancer humanized platform development is ongoing for (a) organoid and (b) in vivo PDX studies for tumor types including ovarian, lung, and breast cancer. Please inquire for an updated list of available tumor types in each platform.

Services

  • Provision of 12 to 14-week BLT or WH mice using fetal tissue or cord blood derived CD34+ stem cells
  • Provision of melanoma PDX mice using NSG.
  • Testing of all mice for levels of reconstitution
  • Transfer/invoice if mice have >20% human CD45+ lymphocytes engraftment
  • Drafts of “grant friendly” text to describe models, grant budget units to include, and support letters
  • Provision of advice on items needed per inclusion of fetal tissue in NIH proposals

Any work related to customized differentiation methods or research use of BLT or WH mice past 12-14 weeks will require collaboration and is outside the scope of Core services. Please reach out to learn more as several labs have added humanized mice into their protocols.

Equipment & Features

  • Dedicated vivarium holding rooms for inoculation and experimentation with humanized and PDX mice
  • Horiba ABX Micros ES 60 Hematology Analyzer

Disclaimer: Resources of the Humanized Models of Disease Core are only available to Wistar researchers and based on availability.


LEARN MORE ABOUT WISTAR’S COMPLIANCE TO THE NEW NIH POLICY

National Institutes of Health (NIH) has introduced new standards for grant applications to address an increasing trend of reports of failure to replicate important basic/preclinical studies.


Contact Us

The Wistar Institute
HMD Facility, Room 315
3601 Spruce Street
Philadelphia, PA 19104
(215) 898-3989

Directors

Luis J. Montaner, D.V.M., M.Sc., D.Phil.,
Co-Scientific Director

Dr. Meenhard Herlyn, D.V.M., D.Sc.,
Co-Scientific Director

Dr. Zhe (Roger) Yuan, Ph.D.,
Managing Director